Health
Designer DNA therapies shown to effectively target cancer stem cells – The Science Board
Using an engineered DNA therapeutic agent to silence transcription factor genes reduced myeloma stem cell abundance and increased the survival of mice bearing human…
Multiple myeloma is the second most common blood cancer in the U.S. It generally recurs and is refractory (reoccurs and is unresponsive to treatments). Despite novel therapies, treatment toxicities continue to be a challenge for patients and clinicians.
In multiple myeloma, proinflammatory cytokines and antiviral interferons derived from bone marrow play a key role in disease progression, including activation of interleukin 6 (IL-6) with downstream interferon-response factor (IRF) signaling.
IRF4…
-
Noosa News16 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General14 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
General15 hours agoSingapore’s world-first sustainable flights tax will see some Australians pay more to travel
-
Noosa News15 hours agoLyka Doggie Date Night at Moonlight Cinema